

RESEARCH ARTICLE

Mean platelet volume and
neutrophil to lymphocyte ratio in
Behçet's Disease

Betul Sereflican¹, Bengu Tuman²,

1. MD, Assistant Professor, Department of Dermatology,
Medical Faculty, AbantIzzetBaysal University, Bolu,
Turkey

2. MD, Research Assistant, Department of Dermatology,
Medical Faculty, AbantIzzetBaysal University, Bolu,
Turkey

Correspondence

BetulSereflican
AbantIzzetBaysal University,
Medical Faculty,
Department of Dermatology,
14280 Golkoy – BOLU,
TURKEY

Keywords

Behçet's Disease, mean
platelet volume, neutrophil
to lymphocyte ratio

Received

06 December 2016

Reviewed

15 December 2016

Accepted

20 December 2016

ABSTRACT

Introduction: Behçet's Disease (BD) is a systemic inflammatory disease. Mean platelet volume (MPV) is a marker of platelet function and the neutrophil to lymphocyte ratio (NLR) is an indicator of inflammation. We investigated the levels of MPV and NLR in patients with BD and healthy individuals. We purposed to investigate the association of NLR and MPV with BD and disease activity.

Methods: Twenty-eight patients diagnosed with BD and 28 healthy subjects were enrolled in this study. Blood samples of patients and controls were measured for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and full blood counts for white blood cells (WBC), MPV and NLR.

Results: The MPV levels in patients with BD were significantly higher than controls ($p=0.002$). The difference in NLR values between patient and control group was not significant ($p=0.068$). No significant difference was found in the NLR values between the patients with and without active lesions ($p = 0.175$). Also there was no significant difference in the MPV values between the patients with and without active lesions ($p=0.35$). There was no correlation between disease duration, disease severity and MPV and NLR values.

Conclusion: The MPV levels may be used as an inexpensive and practical diagnostic marker in patients with BD.

INTRODUCTION

Behçet's Disease (BD) is a multisystemic vasculitis characterized by oral ulcers, genital ulcers, uveitis and involvement of many systems(1). Vascular damage can affect all sizes of venous and arterial vessels. The etiology of BD has not been clarified yet. The disease has been accepted as an autoinflammatory disorder (2). Blood vessels display a nonspecific inflammatory process (3). Vasoconstriction, platelet aggregation may contribute to the vascular injury in BD (4).

Mean platelet volume (MPV) is an indicator of platelet activity and it has been shown to be associated with inflammation severity related with large or small sized platelets. MPV has been defined as a risk factor for atherothrombotic diseases (5,6).

Recently, neutrophil to lymphocyte ratio (NLR) has become popular as a marker to determine inflammation (7). NLR has been used to be a predictor for coronary artery disease, peripheral artery disease (8) and cancers (9).

Since BD is an inflammatory disorder, MPV and NLR values may be changed in patients with BD. The aim of our study is to analyze the association of NLR and MPV with BD and disease activity.

MATERIALS AND METHOD

We enrolled 28 patients with BD who fulfilled the International Study Group (ISG) (10) criteria and a further 28 age- and sex-matched healthy subjects as the control group. Subjects with diabetes mellitus, hypertension, heart failure, previous history of coronary artery disease, liver failure, acute and chronic kidney failure, vitamin B12 and folate deficiency, antihypertensive drugs, lipid-lowering drugs, aspirin, oral contraceptive, hormone, vitamin usage and any other chronic inflammatory disease were excluded from the study.

All patients participating in the study provided written consent. The institutional ethics committee approved the study protocol.

BD patients were divided into two subgroups; those with active and those without active lesions. The presence of oral ulcer, genital ulcer, skin lesions, ocular lesions, arthritis, active major vessel disease or active major organ involvement was considered as active disease. The patients showing no lesions for at least 30 days were considered as being in the inactive stage. The disease severity score was calculated for patients in the active stage (11).

Blood samples of patients were measured for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and full blood counts for white blood cells (WBC), MPV and NLR.

Data analysis was performed using SPSS for Windows (ver.17.0; SPSS Inc., Chicago, IL, USA). The distribution of continuous variables were examined for normality based on the Kolmogorov-Smirnov tests. The data are shown as means \pm standard deviation for continuous variables, medians (minimum–maximum) for ordinal variables, and frequencies with percent for categorical variables. The categorical variables were compared among groups using the chi-square test. Comparisons among the groups were performed using independent sample t-tests or Mann-Whitney U test for normally and abnormally distributed data, respectively. The relationship between disease duration, severity and other continuous variables were analyzed with Spearman analysis. A p-value of 0.05 was considered statistically significant.

RESULTS

The study included 28 patients (18 females, 10 males) with BD and 28 healthy persons (21 females, 7 males). The average age in the patient group was 34.85 ± 9.65 years; in the control group it was $31.53 \pm$

5.10 years. The patients with BD and healthy persons were matched according to age and sex ($p=0.115$, $p=0.383$, respectively). The demographic characteristics of patients are given in Table 1.

MPV values were found to be elevated significantly in patient group compared to the control group ($p=0.002$). Also there was a significant difference between the patient and control group in terms of CRP and ESR ($p=0.000$, $p=0.005$, respectively); but the difference in NLR, WBC, neutrophil and lymphocyte values was not significant (Table 2).

In the patient group, no significant difference was found in the NLR values between the patients with and without active lesions (2.35 ± 0.81 vs. 2.81 ± 0.92 , respectively; $p = 0.175$). Also there was no significant difference in the MPV values between the patients with and without active lesions (9.20 ± 1.24 vs. 9.71 ± 1.67 , respectively; $p=0.35$).

There was no correlation between disease duration, disease severity and MPV and NLR values. In the patient group a positive correlation was found between ESR and CRP, and a negative correlation was found between disease severity and onset of disease ($r=0.530$, $p=0.004$; $r=-0.409$, $p=0.031$, respectively).

DISCUSSION

T cells and polymorphonuclear leukocytes are shown within vasculitic reaction in BD (12). Activated leukocytes are thought to participate in vascular injury in BD. Increased serum levels of von Willebrand factor, plasminogen activator inhibitor-1 and thrombomodulin in patients with BD support the vascular disorder (4). Although acute phase proteins, cytokines, immunoglobulins, complement levels, lymphocytes, thrombogenic markers, cell surface markers can be used as an indicator of activity of BD, there is no specific method of assessing disease activity (13).

NLR was presented as a new biomarker to detect systemic inflammation. It has been demonstrated that NLR may be a marker for inflammation in many diseases such as atherosclerosis, diabetes mellitus, metabolic syndrome, myocardial infarction and psoriasis (14). In the study of Alan et al. NLR values were significantly higher in patients with BD, but there was no correlation between NLR values and disease severity (15). In the study of Öztürk et al. NLR values in the patient group were significantly higher than in the control group. In addition, NLR was higher in patients with active lesions than in those without active lesions (16). In the

study of Rifaioglu et al. NLR was found higher in patients with active BD compared to healthy individuals and those without active lesions (17). In the study of Akkurt et al. NLR values were investigated in patients with BD and uveitis. NLR was significantly higher in patients with BD compared to the control group. Also NLR values were significantly higher during the attack than the post-attack period (18). In the study of Özüğüz et al. NLR was determined higher in the patient group and NLR was significantly higher in the active period of the disease (19). In our study, NLR values in the patient group were higher than the control group, but the difference did not reach statistical significance. Also no significant correlation was found between disease activity, disease severity and NLR values. These results suggest that NLR may not be a reliable indicator of inflammation in BD.

MPV has been accepted as an indicator of proinflammatory and prothrombotic states. Cardiovascular diseases, cerebrovascular diseases, chronic inflammatory disorders, even age, gender may alter MPV values (20). In the study of Ekiz et al., Özüğüz et al. and Acikgoz et al. MPV levels were significantly higher in patients with BD than the control group, but the disease activity did not have a significant impact on the levels of MPV

(19,21,22). In the study of Alan et al. no significant difference was found between BD and the control group in terms of MPV. In the patient group, the levels of MPV in patients with severe disease were significantly higher than the patients with mild disease, but there was no correlation between the severity score of BD and MPV (15). In the study of Balta et al. MPV levels were higher in patients with BD than the control group. In the same study MPV levels correlated positively with arterial stiffness that is accepted as a marker of subclinical atherosclerosis (23). In our study MPV values were found to be significantly high in the patient group compared to the control group in line with findings in most of the previous studies. But we could not find positive correlation with disease severity and MPV levels, also there was no significant difference in MPV levels between BD with and without active stage. Our results support that MPV may be a marker of inflammation and thrombotic tendency seen in patients with BD. The lack of correlation between disease activity/tgseverity and MPV may cause from the lower disease severity score of our patients.

In our study the acute phase reactants, CRP and ESR values were significantly higher in patient group compared to the control group. It has been thought that

CRP is an inflammatory marker and may directly reveal endothelial dysfunction (24, 25). So, these results improve the reliability of our study.

In conclusion, we evaluated MPV and NLR, inexpensively and easily obtained from complete blood counts in our study. NLR was not found to be significantly high contrary to the studies in the literature. According to our results, NLR may not be a reliable marker of inflammation in BD. But MPV values were significantly higher in the patient group than in the control group. MPV may be a practical and cheap indicator of inflammation, even atherothrombosis in BD.

REFERENCE

1. Mat MC, Sevim A, Fresko I, Tüzün Y. Behçet's disease as a systemic disease. *ClinDermatol.* 2014;32(3):435-42.
2. Yazici Y, Yurdakul S, Yazici H. Behçet's syndrome. *CurrRheumatol Rep.* 2010;12(6):429-35.
3. Mat C, Yurdakul S, Sevim A, et al. Behçet's syndrome: facts and controversies. *ClinDermatol.* 2013;31(4):352-61.
4. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients

with Behçet's syndrome. *J Am CollCardiol* 2001;37(2):517-20.

5. Bancroft AJ, Abel EW, McLaren M, Belch JJ. Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. *Platelets*. 2000;11(7):379-87.

6. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. *Platelets* 2002; 13(5-6): 301–306.

7. Demirkol S, Balta S, Kucuk U, Kucuk HO. The neutrophil lymphocyte ratio may be useful inflammatory indicator before applying other expensive and invasive procedures. *Indian J Nephrol*. 2014; 24(1): 65-6.

8. Aykan AÇ, Hatem E, Kalaycıoğlu E, Karabay CY, Zehir R, Gökdeniz T, et al. Neutrophil-to-lymphocyte ratio may be a marker of peripheral artery disease complexity. *Anatol J Cardiol* 2016; 16: 000-000; DOI:10.5152.

9. Huang GQ, Zhu GQ, Liu YL, Wang LR, Braddock M, Zheng MH, Zhou MT. Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. *Oncotarget*. 2016 2;7(5):5429-39.

10. Anon. International Study Group for Behcet's Disease Criteria for Diagnosis of Behcet's disease. *Lancet* 1990;335(8697):1078-80.

11. Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdoğan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. *Ann Rheum Dis*. 1984;43(6):783-9.

12. Saadoun D, Wechsler B. Behçet's disease. *Orphanet J Rare Dis*. 2012;7:20.

13. Tursen U. Activation Markers in Behcet Disease. *Turkderm* 2009; 43 Special Issue 2: 74-86.

14. Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. *Cutan Ocul Toxicol*. 2014;33(3):223-7.

15. Alan S, Tuna S, Türkoğlu EB. The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet's syndrome. *Kaohsiung J Med Sci*. 2015;31(12):626-31.

16. Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, Iyisoy A, Eksioğlu M. Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behçet disease without cardiovascular

involvement. *Angiology*. 2015;66(3):291-6.

17. Rifaioğlu EN, Bülbülşen B, Ekiz Ö, CigdemDogramaci A. Neutrophil to lymphocyte ratio in Behçet's disease as a marker of disease activity. *Acta Dermatovenerol Alp Pannonica Adriat*. 2014;23(4):65-7.

18. Akkurt ZM, Türkcü FM, Uçmak D, Yıldırım A, Yüksel H, Özkurt ZG, Arıca M. The Neutrophil-to-Lymphocyte Ratio is Increased in Patients with Behçet's Disease. *Journal of Kırıkkale University Faculty of Medicine* 2014; 16(3): 4-11.

19. Özüğüz P, Kacar SV, Akci Ö, Balta İ, Karaca S, Kocak M. Can we determine the activity of Behçet's Disease with a more practical and easy method? *Gulhane Med J* 2014; 56(4): 213-217.

20. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitis GD. Mean platelet volume: a link between thrombosis and inflammation? *Curr Pharm Des*. 2011;17(1):47-58.

21. Ekiz O, Balta I, Sen BB, Rifaioğlu EN, Ergin C, Balta S, Demirkol S. Mean platelet volume in recurrent aphthous stomatitis and Behçet disease. *Angiology*. 2014;65(2):161-5.

22. Acikgoz N, Karıncaoğlu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M,

Barutcu I, Pekdemir H, Ozdemir R. Increased mean platelet volume in Behçet's disease with thrombotic tendency. *Tohoku J Exp Med*. 2010;221(2):119-23.

23. Balta I, Balta S, Koryurek OM, Demirkol S, Celik T, Akbay G, Cakar M, Sarlak H, Eksioğlu M. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet's disease without significant cardiovascular involvement. *J Eur Acad Dermatol Venereol*. 2014;28(10):1388-93.

24. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. *Pharmacol Rep*. 2006; 58 Suppl:81-8.

25. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation* 2000; 102(18): 2165-8.

Table 1: Characteristics of patients with BD

| Characteristics | BD (n=28) | Controls (n=28) | <i>p</i> |
|---------------------------|--------------------------|------------------|----------|
| Age, yr | 34.85 ± 9.65 | 31.53 ± 5.10 | 0.115 |
| Male, no(%)-female, no(%) | 10 (%35.7)-18 (%64.3) | 7 (%25)-21 (%75) | 0.383 |
| Onset age of disease, yr | 26.96±8.03 | | |
| Disease duration, months | 66 (12-312) | | |
| Disease severity score | 1 (1-6) | | |

Table 2: Laboratory Parameters in Patients and Control Groups

| | BD | Controls | <i>p</i> |
|--------------------------|---------------------|-------------------|----------|
| WBC (K/uL) | 7.86±2.30 | 7.31±2.12 | 0.352 |
| Neutrophil (K/uL) | 4.87(2.61-9.50) | 4.25(0.70-10.30) | 0.098 |
| Lymphocyte (K/uL) | 2.117±0.581 | 2.135±0.718 | 0.921 |
| NLR | 2.71 (0.97-4.66) | 2.03 (0.24-15.13) | 0.068 |
| MPV (fL) | 9.15 (7.50-12.40) | 8.15 (5.02-12.20) | 0.002 |
| ESR (mm/h) | 16.50 (1.00-107.00) | 8.00 (1.00-36.00) | 0.005 |
| CRP (mg/L) | 5.25 (0.32-75.30) | 0.20 (0.00-22.00) | 0.000 |

BD: Behçet Disease; **CRP:** C-reactive protein; **ESR:** erythrocyte sedimentation rate; **MPV:** mean platelet volume; **NLR:** neutrophil to lymphocyte ratio; **WBC:** white blood cell

& normally distributed data are reported as mean ± standard deviation and compared with t-test; asymmetrically distributed data are reported as median (ranges) and compared with Mann-Whitney U test.